ImetelChat

It seems to me the recent spectacular price action in CPXX is very encouraging for GERN shareholders. Although admittedly not exactly comparable it appears to me that GERN has developed a far superior drug. It is also interesting to note that “the blood cancer market is already valued at over $24 billion per year, and that's for a cohort of treatments that rarely produce durable responses.” http://www.fool.com/investing/general/2 ... trf0000001

Parts of the Fool text seems familiar. Did they recycle on old article?

CPXX: we should not forget that high risk AML is maybe even more agressive and difficult to treat than high risk MF although both are fatal for many. I am really looking forward to the AML trial, certainly after the promising data from the AACR presentation (abstract 2731).

Btw Sargasso: I agree that the CR's in the high risk Mayo MF patients are a probably a deeper kind of response than the high risk AML patients who benefited from Vyxeos. However, it is difficult to compare.